[go: up one dir, main page]

WO2024259412A3 - Combination treatments for depression and other disorders - Google Patents

Combination treatments for depression and other disorders Download PDF

Info

Publication number
WO2024259412A3
WO2024259412A3 PCT/US2024/034303 US2024034303W WO2024259412A3 WO 2024259412 A3 WO2024259412 A3 WO 2024259412A3 US 2024034303 W US2024034303 W US 2024034303W WO 2024259412 A3 WO2024259412 A3 WO 2024259412A3
Authority
WO
WIPO (PCT)
Prior art keywords
depression
nebivolol
intended
depressive disorder
major depressive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/034303
Other languages
French (fr)
Other versions
WO2024259412A2 (en
Inventor
Magid Abraham
Kelsey SATTERLY
Jay Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeuraWell Therapeutics Inc
Original Assignee
NeuraWell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuraWell Therapeutics Inc filed Critical NeuraWell Therapeutics Inc
Publication of WO2024259412A2 publication Critical patent/WO2024259412A2/en
Publication of WO2024259412A3 publication Critical patent/WO2024259412A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides dosage forms that contain both a monoamine oxidase inhibitor (MAOI) and a beta blocker (e.g., propranolol, metoprolol, carvedilol, timolol, carteolol, atenolol, nebivolol, sotalol, bucindolol, nadalol, celirpolol, nebivolol, betaxolol, esmolol, bisoprolol, oxprenolol, penbutolol, labetalol, acebutolol, and pindolol) and methods of making and using same in, for example, for the treatment of psychiatric disorders (e.g., depression, major depressive disorder, major depressive disorder with anxious distress, treatment resistant depression, anxious depression, and mixed anxiety and depression). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
PCT/US2024/034303 2023-06-16 2024-06-17 Combination treatments for depression and other disorders Pending WO2024259412A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202363521578P 2023-06-16 2023-06-16
US63/521,578 2023-06-16
US202363528285P 2023-07-21 2023-07-21
US63/528,285 2023-07-21
US202463638117P 2024-04-24 2024-04-24
US63/638,117 2024-04-24

Publications (2)

Publication Number Publication Date
WO2024259412A2 WO2024259412A2 (en) 2024-12-19
WO2024259412A3 true WO2024259412A3 (en) 2025-05-15

Family

ID=93852723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034303 Pending WO2024259412A2 (en) 2023-06-16 2024-06-17 Combination treatments for depression and other disorders

Country Status (1)

Country Link
WO (1) WO2024259412A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013879A1 (en) * 1997-09-17 1999-03-25 Sanofi-Synthelabo Pharmaceutical compositions containing a monoamine oxydase inhibitor and their use in therapy
US20100143507A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
US20220117975A1 (en) * 2019-02-17 2022-04-21 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
US20220265672A1 (en) * 2021-02-23 2022-08-25 Hoth Therapeutics, Inc. Use of aprepitant for treating alzheimer's disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013879A1 (en) * 1997-09-17 1999-03-25 Sanofi-Synthelabo Pharmaceutical compositions containing a monoamine oxydase inhibitor and their use in therapy
US20100143507A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
US20220117975A1 (en) * 2019-02-17 2022-04-21 Neurawell Therapeutics Compositions and methods for treatment of depression and other disorders
US20220265672A1 (en) * 2021-02-23 2022-08-25 Hoth Therapeutics, Inc. Use of aprepitant for treating alzheimer's disease

Also Published As

Publication number Publication date
WO2024259412A2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
US4153717A (en) Analgesic N-(2-(furylmethylamino and 2 -thienylmethylamino)cyclo aliphatic)benzamides
WO2024259412A3 (en) Combination treatments for depression and other disorders
US4070401A (en) Method for the preparation of a halogenated aromatic amine
RU2010112816A (en) APPLICATION OF A BLOCK-BLOCKER FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF HEMANGIOMAS
US4960941A (en) Hydrogenation of aromatic amines to produce their ring hydrogenated counterparts
EP0992284A2 (en) Catalyst and process for the selective hydrogenation of unsaturated components in hydrocarbon streams
WO2004007425A3 (en) Process for increasing the selectivity of the hydrogenation of 4,4&#39;-diaminodiphenylmethane to 4,4&#39;-diaminodicyclohexylmethane in the presence of an n-alkyl-4,4&#39;-diaminodiphenylmethane
RU2004128337A (en) METHOD FOR PRODUCING PRIMARY AMINES BY HYDROGENING NITRILES
JP4874749B2 (en) Hydrogenation of aromatic amines to alicyclic amines with lithium aluminate catalysts
US20030158253A1 (en) Ethers of O-Desmethyl venlafaxine
US20060074131A1 (en) Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
Moyer et al. Central stimulation of respiration during hypoxia
ZA202310714B (en) A hydrogenation catalyst and its precursor comprising ni, al, and a support material comprising sio2
US5550294A (en) Method of increasing hydrogenation rate of aromatic amines
US6492558B2 (en) Preparation of n-butylamines
KR102103768B1 (en) Optically active 2-amino-4-alkoxypyrimidnes derivatives as 5-HT2C agonists
US4197308A (en) Analgesic N-(2-heterocyclic-amino cycloaliphatic) benzamides
GB763434A (en) Manufacture of alkanolamines
US20250034064A1 (en) Synthesis, process development and optimization of hydrogenated alpha methyl styrene dimer
Zaugg et al. 2, 2-Diphenyl-1, 3-propanediamines and N-substituted derivatives
TERA et al. Agents for the Treatment of Overactive Detrusor. VIII. 1 “’
SU569559A1 (en) Method of preparing -aminophenols
CR7723A (en) DERIVATIVES OF AZAHETEROCICLILMETILO BENZODIOXANOS FUSIONATED WITH ANTIDEPRESSIVE HETEROCICLES
US5149809A (en) Synthesis of 2-alkylhexahydropyrimidines from nitriles
GB607772A (en) Improvements in or relating to the production of 1-(3,4-dihydroxyphenyl)-2-amino-1-butanol and new intermediates thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824340

Country of ref document: EP

Kind code of ref document: A2